SALT LAKE CITY, UT, UNITED STATES, September 25, 2025 /EINPresswire.com/ — Sethera Therapeutics, a biotechnology company advancing next-generation polymacrocyclic peptide therapeutics, today announced the appointment of two globally recognized scientists, Jeffery W. Kelly, PhD (Scripps Research), and Alexander M. Klibanov, PhD (MIT), to its Scientific Advisory Board (SAB). They join existing SAB member Dr. Robert Langer (MIT) in guiding Sethera’s scientific strategy.